Skip to content

Jazz Pharma gets FDA OK for leukemia med

August 3, 2017

Jazz Pharmaceuticals, a drug developer based in Ireland that is in the process of expanding its U.S. presence in Philadelphia, received Food and Drug Administration approval Thursday for its experimental leukemia treatment.

The FDA approved Vyxeos as an injectable therapy for adults with two types of acute myeloid leukemia, a rapidly progressing and life-threatening blood cancer.

Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals (Nasdaq: JAZZ), said Vyxeos is the first new chemotherapy advance in more than 40 years for adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.

“The FDA approval of Vyxeos reflects our commitment to addressing unmet needs within the hematology oncology community,” Cozadd said.

Vyxeos is the first product developed with the company’s proprietary CombiPlex platform, which enables the design and rapid evaluation of various combinations of therapies. With Vyxeos, the technology delivers a fixed-ratio of daunorubicin and cytarabine to the bone marrow to kill leukemia cells.

Jazz Pharmaceuticals expects to have Vyxeos commercially available within a week.

Earlier this summer, the company signed a lease deal for 46,000 square feet of office space at Commerce Square in Center City near its current Philadelphia offices. It plans to move into the new space next year.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: